Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mass Balance, Pharmacokinetics, and Metabolism of [^14C]-Alisertib in Patients With Advanced Solid Tumors or Lymphomas

Trial Profile

Mass Balance, Pharmacokinetics, and Metabolism of [^14C]-Alisertib in Patients With Advanced Solid Tumors or Lymphomas

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Nov 2018

At a glance

  • Drugs Alisertib (Primary)
  • Indications Bladder cancer; Lymphoma; Mesothelioma; Ovarian cancer; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Millennium; Takeda
  • Most Recent Events

    • 06 Nov 2018 Results published in the Investigational New Drugs
    • 23 Oct 2013 Results for part A presented at the 25th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
    • 01 Aug 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top